Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma

NCT00714948 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Lack of accrual

Conditions

Bladder Cancer
URINARY BLADDER

Interventions

DRUG: gemcitabine and cisplatin plus sorafenib

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]